,i #aaith ,,congress #b;d ,session ,h4 ,r4 #iggd ,,in ,,the ,,house ,,of ,,representatives ,july #bj1 #bjbf,mr4 ,latta 7for himself and ,mr4 ,landsman7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to provide for expedited approval of priority nonprescription drugs1 and for other purposes4 #a4 ,priority nonprescription drugs 7a7 ,in general ,the ,federal ,food1 ,drug1 and ,cosmetic ,act is amended by inserting after section #ejf,l 7#ba ,u4,s4,c4 #cefl7 the following3 #ejf,m4 ,priority nonprescription drugs 7a7 ,in general 7#a7 ,designation ,the ,secretary may1 at the request of the sponsor of a nonprescription drug1 designate as a priority nonprescription drug under this section a drug intended for nonprescription use that is subject to an application submitted 7or to be submitted7 under section #eje7;b71 if the ,secretary determines that the drug meets the criteria specified in subsection 7d74 7#b7 ,nonprescription defined ,in this section1 the term nonprescription means1 with respect to a drug1 that such drug is not subject to section #ejc7;b77#a74 7b7 ,request for designation ,the sponsor of a drug subject to a pending application under section #eje7;b7 for nonprescription use may request that the ,secretary designate the drug as a priority nonprescription drug4 7c7 ,designation ,not later than #fj calendar days after the receipt of a request under subsection 7b71 the ,secretary shall determine whether a drug meets the criteria for designation as a priority nonprescription drug under this section1 and if so1 make such designation4 7d7 ,criteria 7#a7 ,eligibility ,except as provided in paragraph 7#b71 a drug described in subsection 7a7 is eligible for designation as a priority nonprescription drug if-- 7,a7 the drug is intended for a novel nonprescription indication that could provide a meaningful public health benefit2 7,b7 the drug is a new molecular entity2 or 7,c7 the drug contains an active ingredient that has never been available in a nonprescription drug4 7#b7 ,exclusion ,a drug is not eligible for designation as a priority nonprescription drug if the drug is subject to a risk evaluation and mitigation strategy under section #eje-a or if the drug is a controlled substance 7as defined in section #ajb of the ,controlled ,substances ,act74 7e7 ,actions ,if the ,secretary designates a drug as a priority nonprescription drug1 the ,secretary shall take such actions as are appropriate to facilitate the development of1 and expedite the review of1 an application or supplement to an application for such drug1 which may include-- 7#a7 holding meetings with the sponsor and the review team throughout the development of the drug2 7#b7 providing timely advice to1 and interactive communication with1 the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary to demonstrate the inapplicability of the criteria described in section #ejc7;b77#a7 is as efficient as practicable2 7#c7 involving senior managers and experienced review staff1 as appropriate1 in a collaborative1 cross-disciplinary review2 7#d7 assigning a cross-disciplinary project lead for the ,food and ,drug ,administration team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor2 and 7#e7 taking steps to ensure that the design of any necessary nonclinical or clinical trials is as efficient as practicable1 when scientifically appropriate1 including reliance on real world evidence4 7f7 ,list of conditions 7#a7 ,establishment ,not later than #ah months after the date of enactment of this section1 the ,secretary shall publish in the ,federal ,register a list of conditions for which a nonprescription drug1 if developed for the condition1 could provide meaningful public health benefit4 7#b7 ,public comment ,the ,secretary shall provide a period of not less than #cj days for public comment on-- 7,a7 the list under paragraph 7#a72 and 7,b7 any updates to such list4 4 7b7 ,rule of construction ,the amendment made by subsection 7a7 shall not be construed to alter the evidentiary standards or the information required for approval of a nonprescription drug under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee74 7c7 ,report to ,congress ,not later than #d years after the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services shall submit to ,congress a report containing-- 7#a7 the number of nonprescription drugs for which a sponsor requested that the ,secretary designate such a drug as a priority nonprescription drug under section #ejf,m of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by subsection 7a72 7#b7 the number of nonprescription drugs for which the ,secretary approved such request2 7#c7 the number of priority nonprescription drugs 7as designated under such section7 for which the ,secretary approved an application under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee72 7#d7 an overview of the resources used to implement such section2 and 7#e7 any recommendation on further improvement on increasing over-the-counter drug approvals using a framework similar to the designation framework established in such section4 7d7 ,sunset date ,the authority provided to the ,secretary of ,health and ,human ,services under section #ejf,m of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by subsection 7a71 shall cease to be effective ,september #cj1 #bjcb4